Stay updated with breaking news from Covid Based Therapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A new study by investigators from Mass General Brigham found that one in five individuals taking Nirmatrelvir-ritonavir therapy, commonly known as Paxlovid, to treat severe symptoms of COVID-19, experienced a positive test result and shedding of live and potentially contagious virus following an initial recovery and negative test—a phenomenon known as virologic rebound.
A trial study of veterans with COVID-19 found that the use of the antiviral paxlovid was not effective for reducing the risk for many post-COVID-19 conditions, including cardiac, pulmonary, renal, gastrointestinal, neurologic, mental health, musculoskeletal, or endocrine symptoms.
The COVID-19 treatments millions of Americans have taken for free from the federal government will enter the private market next week with a hefty price tag.
A month after federal officials recommended new versions of COVID-19 vaccines, 7% of U.S. adults and 2% of children have gotten a shot.
Researchers have identified 38 businesses engaged in direct-to-consumer marketing of purported stem cell treatments and exosome therapies for preventing and treating COVID-19 even though these “interventions” have not been approved or authorized by national regulatory bodies and are not supported by convincing safety and efficacy data.